Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 9, pp 2596–2602 | Cite as

Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

  • Toan T. Nguyen
  • Tanya L. Hoskin
  • Courtney N. Day
  • Amy C. Degnim
  • James W. Jakub
  • Tina J. Hieken
  • Judy C. Boughey
Breast Oncology

Abstract

Background

Neoadjuvant chemotherapy (NAC) may downstage axillary disease in node-positive breast cancer. Several clinical trials have shown that sentinel lymph node (SLN) surgery after NAC is feasible for these patients. We sought to evaluate the use of SLN surgery and ALND in cN1 patients undergoing NAC.

Methods

We identified all patients with biopsy-proven cN1 breast cancer treated with NAC at our institution between January 2009 and December 2017. Approximated biologic subtype was determined by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status. Cochran–Armitage trend and Chi square tests were used for statistical analysis.

Results

Of 430 cN1 patients treated with NAC, 93 (22%) underwent SLN surgery only, 100 (23%) underwent SLN and ALND, and 237 (55%) underwent ALND only. The use of SLN surgery (± ALND) increased from 28% in 2009 to 86% in 2017 (p < 0.001), while the performance of ALND decreased from 100% in 2009 to 38% in 2017 (p < 0.001). Among SLN+ patients who underwent ALND, disease was limited to the SLNs in 25/73 (34%) patients. The nodal pathologic complete response rate was 46% and varied by tumor subtype (p < 0.001). Among patients undergoing SLN surgery, ALND was avoided in 48% of patients overall and varied by biologic subtype: 55% ER−/HER2+, 61% ER+/HER2+, 62% ER−/HER2−, and 31% ER+/HER2− (p = 0.001). With short-term follow-up, no nodal recurrences have occurred in patients without ALND.

Conclusions

We observed a significant shift in axillary surgery for cN1 breast cancer patients treated with NAC, with increasing use of SLN surgery to assess nodal treatment response, and decreasing use of ALND.

Notes

Funding/Support

None.

Conflict of interest

Toan T. Nguyen, Tanya L. Hoskin, Courtney N. Day, Amy C. Degnim, James W. Jakub, Tina J. Hieken, and Judy C. Boughey have no conflicts of interest to declare.

References

  1. 1.
    Caudle AS, Hunt KK, Tucker SL, et al. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Ann Surg Oncol 2012;19(10):3144–51.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21(22):4165–74.CrossRefPubMedGoogle Scholar
  3. 3.
    Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg 2015;262(3):434–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;(30):96–102.CrossRefGoogle Scholar
  5. 5.
    Dominici LS, Negron Gonzalez VM, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 2010;116(12):2884–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999;230(1):72–8.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 2014;260(4):608–14; discussion 614-6.Google Scholar
  8. 8.
    Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23(16):3676–85.CrossRefPubMedGoogle Scholar
  9. 9.
    Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11(10):927–33.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013;310(14):1455–61.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013;14(7):609–18.CrossRefPubMedGoogle Scholar
  12. 12.
    Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study. J Clin Oncol 2015;33(3):258–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802-7CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mamtani A, Barrio AV, King TA, et. al. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Ann Surg Oncol. 2016;23(11):3467–74.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    National Comprehensive Cancer Network. Breast Cancer (Version 4.2017). Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 19 Mar 2018.
  16. 16.
    El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg. 2016;212(5):969–81.CrossRefGoogle Scholar
  17. 17.
    Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016;34(10):1072–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 2015;261(2):378–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Vugts G, Maaskant-Braat AJ, de Roos WK, Voogd AC, Nieuwenhuijzen GA. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands. Eur J Surg Oncol 2016;42(7):956–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol 2016;42(3):361–8.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Toan T. Nguyen
    • 1
  • Tanya L. Hoskin
    • 2
  • Courtney N. Day
    • 2
  • Amy C. Degnim
    • 1
  • James W. Jakub
    • 1
  • Tina J. Hieken
    • 1
  • Judy C. Boughey
    • 1
  1. 1.Department of SurgeryMayo ClinicRochesterUSA
  2. 2.Department of Health Sciences ResearchMayo ClinicRochesterUSA

Personalised recommendations